NMD4C Receives Network Grant from CIHR-IMHA and Funding from MDC

We are excited to share that The Neuromuscular Disease Network for Canada (NMD4C) has received a network grant from the Canadian Institutes of Health Research – Institute of Musculoskeletal Health and Arthritis (CIHR-IMHA), providing funding of $200 000 per year for five years – with matched funding from Muscular Dystrophy Canada (MDC) –  to strengthen the care, research and treatment of neuromuscular diseases (NMDs) for all Canadians. The new grant brings together an expanded group of clinicians, scientists and patient representatives under the leadership of Dr Hanns Lochmüller (Children’s Hospital of Eastern Ontario) and Dr Homira Osman (MDC).

“Since 2020, NMD4C has made remarkable progress in uniting Canada’s neuromuscular community. In these rare diseases it’s crucial that we work together, and we’re delighted that we have grown to more than 500 members spanning multiple disciplines, sectors, and areas of expertise. The network has made tremendous strides in building capacity through training and education, providing leadership and advocacy to improve access to approved novel treatments, and strengthening research resources and infrastructure. But there’s still so much more to be done. New scientific challenges and opportunities mean that networking across Canada and the globe is even more important. This new funding will allow us to expand our supportive, collaborative, networked community of neuromuscular stakeholders, bringing together an unparalleled concentration of NMD expertise to provide a Canada-wide platform for communication, collaboration, and best-practice sharing. We’re very grateful to CIHR-IMHA and to MDC for the funding that allows us to continue our work. We have some really exciting plans for this next phase of the network, particularly for our young doctors and researchers, and we can’t wait to get started.”

– Dr Hanns Lochmüller

 

Read the full press release here

xr:d:DAFmd0iKQEo:9,j:7891826583529976397,t:23062115

Read next...

haleyozgefinal

Two Research Lab Members Receive CIHR Funding Awards!

We are excited to share that two of our research team members have received competitive funding awards from the Canadian Institutes of Health Research (CIHR)...
Hanns CRC image (1)

Dr. Hanns Lochmüller’s Canada Research Chair Renewed Through 2032

We are pleased to announce that Dr. Hanns Lochmüller’s Tier 1 Canada Research Chair (CRC) in Neuromuscular Genomics and Health has been renewed through the...
kiran scientist

Dr. Kiran Polavarapu Appointed Scientist at the CHEO Research Institute

We are delighted to congratulate Dr. Kiran Polavarapu on his appointment as Scientist at the Children’s Hospital of Eastern Ontario Research Institute (CHEO RI). This...
welcome

Meet The Lab’s New Clinical Members!

Our research team is growing! We are excited to announce three new research staff who have joined the lab this winter, as well as two...
researcher of the year 2025

Dr. Hanns Lochmüller Awarded “Clinical Researcher of the Year” by University of Ottawa Faculty of Medicine

We are thrilled to announce that Dr. Hanns Lochmüller has been awarded the Clinical Researcher of the Year Award by the University of Ottawa Faculty...
Holland study

New Publication: Galactose treatment rescues neuromuscular junction transmission in glutamine-fructose-6-phosphate transaminase 1 (Gfpt1) deficient mice

Congenital Myasthenic Syndromes (CMS) are a group of rare inherited neuromuscular disorders caused by genetic defects at the neuromuscular junction (NMJ). Patients with CMS experience...